MCM
SRPT icon

Mason Capital Management’s Sarepta Therapeutics SRPT Stock Holding History

Mason Capital Management’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-175,000
Closed -$3.42M – 21
2016
Q1 		$3.42M Buy
+175,000
New +$3.06M 0.11% 17

Other funds holding SRPT

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Mason Capital Management's SRPT Position: Q2 2016 in Review

Mason Capital Management sold out of Sarepta Therapeutics (SRPT) in Q2 2016, closing a stake of 175,000 shares — an estimated $3.42M sold.

Mason Capital Management first reported a position in SRPT in Q1 2016 and held it in 1 quarter. The position peaked at $3.42M in Q1 2016. 148 funds tracked by Wall St. Rank hold SRPT as of Q2 2016.

  • Mason Capital Management reported no remaining Sarepta Therapeutics position as of Q2 2016 after selling out during the quarter.
  • Mason Capital Management sold 175,000 Sarepta Therapeutics shares in Q2 2016, an estimated $3.42M.
  • Mason Capital Management first reported a position in Sarepta Therapeutics in Q1 2016 and held it in 1 quarter.
  • Mason Capital Management's Sarepta Therapeutics position peaked at $3.42M in Q1 2016.
  • 148 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2016.

Based on Mason Capital Management's 13F filing for Q2 2016, filed 15 Aug 2016.